Liminatus Pharma, Inc. (LIMN): Capital Expenditures

Annual figures by period end, from SEC filings.

$13.1K

Year ended 2025-12-31

Period ended	Capital Expenditures	Change YoY	Source filing
2025-12-31	$13.1K	n/a	2026-03-31, From 2025-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Capital Expenditures	Change YoY
Liminatus Pharma, Inc. (LIMN)	2025-12-31	$13.1K	n/a
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	$23.0K	n/a
BioCardia, Inc. (BCDA)	2025-12-31	$7.0K	+16.7%
Tevogen Inc. (TVGN)	2025-12-31	$64.4K	n/a
AIM ImmunoTech Inc. (AIM)	2024-12-31	$18.0K	n/a
Exozymes Inc. (EXOZ)	2025-12-31	$169.9K	-57.1%
Silexion Therapeutics Corp (SLXN)	2025-12-31	$9.0K	-59.1%
VivoSim Labs, Inc. (VIVS)	2026-03-31	$0	-100.0%
Scinai Immunotherapeutics Ltd. (SCNI)	2025-12-31	$24.0K	+100.0%

Compare LIMN, ZEOX, BCDA, TVGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗